報價延遲最少15分鐘:2025/07/05 23:41 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.4 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-32.16/-35.22
|
|
企業價值
2.82M
|
| 資產負債 |
|
每股賬面淨值
0.91
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/05 23:41 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia. |